Category icon
Pharmacotherapy in Stable CAD: The ISCHEMIA Trial

Jonathan Yap, Derek P Chew, Gregg W Stone, et al

Category icon
2020 APSC Consensus Recommendations on P2Y12 Inhibitor Use

Jack WC Tan, Derek P Chew, Muhamad Ali SK Abdul Kader, et al

Category icon
Ticagrelor Monotherapy Versus Ticagrelor Plus Aspirin

Johny Nicolas, Usman Baber, Roxana Mehran,

Category icon
Antithrombotic Therapy After TAVI

Leslie Marisol Lugo, Rafael Romaguera, Joan Antoni Gómez-Hospital, et al

Category icon
Antithrombotic Treatment After Coronary Intervention

Tamara García Camarero, José M de la Torre Hernández,

Category icon
Antithrombotics in TAVR

Mathew R Williams, Kelsey Grossman, Homam Ibrahim,

Category icon
Cost-effectiveness of Guided Antiplatelet Therapy

Nikita Lomakin, Anna Rudakova, Liudmila Buryachkovskaya, et al

Category icon
NOACs After ACS: Is There a Role?

Paul Guedeney, Birgit Vogel, Roxana Mehran,

Category icon
Anticoagulant Therapy for Acute Coronary Syndromes

Eunice NC Onwordi, Amr Gamal, Azfar Zaman,

About

Dual anti-platelet therapy (DAPT) with aspirin and a P2Y12 inhibitor is the current gold standard for the treatment of acute coronary syndrome (ACS). Clopidogrel or ticagrelor are the preferred P2Y12 inhibitor options for initial therapy. Ticagrelor has been demonstrated to have improved efficacy, and is preferred over clopidogrel in the absence of contraindications or the need for oral anticoagulation.

The main risk associated with all antiplatelet therapies is bleeding, and physicians need to carefully weigh the possible adverse effects against the benefits of prescribing these drugs to patients with ACS. Aspirin continues to be prescribed almost ubiquitously for patients with ACS, and P2Y12 antagonists are now often added in; such dual antiplatelet therapy confers greater antithrombotic efficacy but at the risk of increased bleeding. Over recent years, it has become apparent that these drugs may also exert powerful anti-inflammatory effects that provide additional benefit in the management of ACS.

Related Articles

Articles

Article icon
Pharmacotherapy in Stable CAD: The ISCHEMIA Trial

Jonathan Yap, Derek P Chew, Gregg W Stone,

Published:

Citation: European Cardiology Review 2021;16:e04.

2020 APSC Consensus Recommendations on P2Y12 Inhibitor Use

Jack WC Tan, Derek P Chew, Muhamad Ali SK Abdul Kader,

Published:

Citation: European Cardiology Review 2021;16:e02.

Ticagrelor Monotherapy Versus Ticagrelor Plus Aspirin

Johny Nicolas, Usman Baber, Roxana Mehran,

Published:

Citation: US Cardiology Review 2020;14:e04.

Antithrombotic Therapy After TAVI

Leslie Marisol Lugo, Rafael Romaguera, Joan Antoni Gómez-Hospital,

Published:

Citation: European Cardiology Review 2020;15:e09.